Figure 2
Survival for previously untreated chronic-phase patients who received imatinib 400 mg daily as initial therapy for newly diagnosed CML in chronic phase. The curves show the estimated cumulative best complete hematologic response, major cytogenetic response, and complete cytogenetic response rates, respectively, at 5 years from start of therapy. The vertical dotted lines show the 1- and 5-year values. Reprinted with permission from Druker et al.10 © 2006 Massachusetts Medical Society. All rights reserved.
